Jazz Pharmaceuticals revealed that presentations taking place at the 2023 American Epilepsy Society (AES) annual meeting will include long-term and real-world data about treatment-resistant epilepsy.
Taking place at the 2023 American Epilepsy Society (AES) annual meeting, Jazz Pharmaceuticals, a global biopharmaceutical company, disclosed that there will be nine company-sponsored presentations which include five late-breaking abstracts covering Epidiolex® data in a recent press release (1). The meeting will be taking place in Orlando, Florida, on December 1-5, 2023.
Epidiolex® (cannabidiol [CBD]) is a drug used for treatment-resistant epilepsy such as those seen in patients who have Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) (1). Presentations at AES will showcase long-term and real-world results from the Expanded Access Program (EAP), GWPCARE6 Open-Label Extension (OLE) trial, the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) (tuberous sclerosis complex [TSC]), and more (1).
"Multiple presentations at the 2023 AES meeting continue to build the scientific evidence in support of Epidiolex and improve understanding around the treatment's full impact," Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals mentioned (1). "In addition to seizure outcomes, the BECOME studies are also designed to assess non-seizure benefits of Epidiolex, such as cognition and executive function, emotional and social function, and language and communication. We are determined to not only address seizure outcomes for patients living with rare epilepsies, but also improve the day-to-day lives for both patients and their loved ones."
In Jazz Pharmaceuticals press release, they announced a few of the data highlights which will be shared during the meeting (1):
To view the AES abstracts, please visit (2): https://aesnet.org/education/annual-meeting/aes-abstract-search.
References
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.